The use of gold markers and electronic portal imaging for radiotherapy verification in prostate cancer patients: Sweden Ghana Medical Centre experience

• Main Author: George Felix Acquah
• Format: Article
• Language: English
• Published: IJCTO 2014-02-01
• Series: International Journal of Cancer Therapy and Oncology
• Subjects: Prostate Cancer; Gold Markers; Treatment Verification; EPID; DRRs
• Online Access: http://ijcto.org/index.php/IJCTO/article/view/57

<p>The success of radiotherapy cancer treatment delivery depends on the accuracy of patient setup for each fraction. A significant problem arises from reproducing the same patient position and prostate location during treatment planning for every fraction of the treatment process. To analyze the daily movements of the prostate, gold markers are implanted in the prostate and portal images taken and manually matched with reference images to locate the prostate. Geometrical and fiducial markers are annotated onto a highly quality generated digitally reconstructed radiographs, that are compared with portal images acquired right before treatment dose delivery. A 0 and 270 degree treatment fields are used to calculate prostate shifts for all prostate cancer patients undergoing treatment at the Sweden Ghana Medical Centre, using an iViewGT portal imaging device. After aligning of the marker positions onto the reference images, the set-up deviations corrections are displayed and an on-line correction procedure applied. The measured migrations of the prostate markers are below the threshold of 3 mm for the main plans and 2 mm for the boost plans. With daily electronic portal imaging combined with gold markers, provides an objective method for verifying and correcting the position of the prostate immediately prior to radiation delivery.</p><p>--------------------------------------------</p><p><strong>Cite this article as:</strong> Acquah GF. The use of gold markers and electronic portal imaging for radiotherapy verification in prostate cancer patients: Sweden Ghana Medical Centre experience. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):020112.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.12" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.12</a></p>